ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to significant stock price decline [8]. Allegation Details - The lawsuit claims that Altimmune provided inflated expectations prior to the announcement of the trial results, which revealed a failure to achieve statistical significance in the primary endpoint of fibrosis reduction [8]. - Following the announcement on June 26, 2025, Altimmune's stock price plummeted from $7.71 to $3.61, marking a 53.2% decline in one day [8]. Next Steps - Investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, are encouraged to contact the law firm for more information and to discuss their legal rights [4][8].